Pipeline

FIRST-IN-CLASS NCE ENB003 AND ENB001:

Potential Synergy with Multiple Immuno-oncology Platforms

ENLARGE GRAPHIC

MECHANISM OF ACTION

ENLARGE GRAPHIC

ENB003- Lead compound

  • Deuterium exchanged, small molecule NCE
  • Highly potent and selective ETBR inhibitor
  • Composition of matter issued 2019
  • Launch in initial target indications (non-central nervous system, CNS)
  • Orphan Drug designation for melanoma awarded by FDA
  • Currently being evaluated in clinical trials in collaboration with Merck

ENB004

  • 2nd Gen ETBR inhibitor
  • Highly potent and selective ETBR inhibitor
  • Orally bioavailable
  • Preclinical development

ENB005

  • 2nd Gen ETBR inhibitor
  • Being developed for BBB penetration
  • Discovery phase

ENB006

  • Nanoparticle formulation of ENB-003
  • Being developed for enhanced CNS penetration
  • Discovery phase

ENB’s Advantage

ENLARGE GRAPHIC

Get in touch

Contact Us